Insulins are a class of drugs used to treat type 1 (T1DM) and type 2diabetes mellitus(T2DM). T1DM is a condition caused by anautoimmunereaction that destroys the beta cells of the pancreas because of which the body cannot produce or synthesizeinsulinneeded to manage circulating blood sugar le...
Related Drugs Drug Name Total Prescriptions (2022) Insulin Glargine 18,983,906 Insulin Lispro 9,647,314 Insulin Aspart (this drug) 8,813,259 Insulin Detemir 4,867,208 Insulin Degludec 4,306,212 Therapeutic Classes Antidiabetic Agents Insulin Metabolic Agents...
Glulisine insulin is the latest addition to the class of rapid-acting insulin analogues. It is important that it is comparable in safety not only to human regular insulin, but also to the well established analogue insulins, aspart and lispro. In this summary the evidence comparing the safety ...
5.1.1.2 Levemir (Insulin Detemir) 5.1.1.3 Toujeo (Insulin Glargine) 5.1.1.4 Tresiba (Insulin Degludec) 5.1.1.5 Basaglar (Insulin Glargine) 5.1.2 Bolus or Fast Acting Insulins 5.1.2.1 NovoRapid/Novolog (Insulin Aspart) 5.1.2.2 Humalog (Insulin Lispro) 5.1.2.3 Apidra (Insulin Glulisine) 5.1...
Examples of DDIs in DrugBank only include acebutolol/Insulin Lispro and metronidazole/terfenadine. Examples of DDIs in NDF-RT only include amiodarone/sotalol and meperidine/linezolid. When we only consider DDIs from the reference set, the overlap between DrugBank and NDF-RT is significantly ...
To reduce postprandial glycemic excursions in patients, ultra-rapid-insulin formulations in a combination of novel excipients with hexamer insulins have been developed by various companies and brought to the market, such as insulin apart with nicotinamide (Novo Nordisk) and insulin lispro with citrate...
The study for a time period of 52 weeks resulted in significant decrease in HbA1c, weight reduction and lower risk of hypoglycaemia in case of dulaglutide with lispro as compared to glargine. [172] AWARD 9 was a 28 week study conducted with once a week dulaglutide with titrated insulin glarg...
Rapid-acting insulins are a class of drugs used to control high blood sugar in people with type 1 (T1DM) and type 2 diabetes mellitus (T2DM) along with a proper diet and exercise.
Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Ra...
An alternative form of insulin suitable for use in the drug-oligomer conjugates of the present invention is insulin lispro, a newly developed analogue of human insulin in which the positions of the amino acids lysine and proline have been switched at the end of the β chain of the insulin ...